Patient Reported Outcomes Burdens and Experiences - Phase 3 (PROBE-3)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03549858|
Recruitment Status : Recruiting
First Posted : June 8, 2018
Last Update Posted : June 8, 2018
|Condition or disease||Intervention/treatment|
|Hemophilia Chronic Disease||Other: Quality of life measure (survey)|
The PROBE questionnaire is a tool for the assessment of patient-reported outcome, burdens and experiences. Until now, it has been used in persons living with hemophilia (PWH) and healthy controls. In phase 1 of the study, the investigators developed the questionnaire. In phase 2 of the study, the investigators evaluated the reliability, reproducibility, responsiveness, and costs of PROBE. The tool has been tested across 21 countries and it has been shown that PROBE is a valid questionnaire for the evaluation of patient reported outcomes (PROs) in PWH and control populations. The questionnaire is available in 11 languages (with 20 localized versions worldwide), and another 17 languages and 45 more localizations are in the process of development.
CURRENT STUDY and FUTURE DIRECTIONS
Phase 3 is the natural prosecution of the project. In this phase, the investigators aim at maintaining the capacity to collect data on PROBE, and the infrastructure will also be modified in order to allow for longitudinal collection of PROBE data (in previous phases, the investigators only collected anonymized data).
The objective of the study is to compare data on PROBE between countries, within-countries over time, and within-countries against national normative data. Reports will be produced every 2 years. Data collected during phase 2 of the study will also be used.
At the same time, the research framework will have the potential for:
- Expanding country participation within existing and new regions.
- Integrating the PROBE questionnaire in clinical trials, longitudinal studies, health technology assessment studies, routine clinical care, and registries.
- Using PROBE in new countries
- Testing the performance of the PROBE questionnaire in new patient populations
Mark Skinner JD, Institute for Policy Advancement Ltd. (US)
- Alfonso Iorio MD Ph.D. FRCPC, McMaster University, Department of Clinical Epidemiology and Biostatistics (Canada)
- Randall Curtis MBA, Factor VIII Computing (US)
- Neil Frick MS, National Hemophilia Foundation (US)
- Michael Nichol Ph.D., University of Southern California, School of Policy and Planning Development (US)
- Declan Noone, Irish Hemophilia Society (Ireland)
- David Page, Canadian Hemophilia Society (Canada)
- Jeff Stonebraker Ph.D., North Carolina State University Poole College of Management (US)
- Brian O'Mahoney, Irish Hemophilia Society (Ireland)
- Chatree Chai-Adisaksopha, MD MSc.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||1000 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Patient Reported Outcomes Burdens and Experiences (PROBE) - Phase 3 - Longitudinal Data Collection|
|Actual Study Start Date :||January 1, 2018|
|Estimated Primary Completion Date :||December 31, 2025|
|Estimated Study Completion Date :||December 31, 2026|
- Other: Quality of life measure (survey)
The QoL tool is a questionnaire
- Between-countries variability of the PROBE score [ Time Frame: 2 years ]Mean difference and standard deviation of the PROBE score between countries.
- Within-countries variability of the PROBE score [ Time Frame: 2 years ]Mean difference and standard deviation of the PROBE score in repeated assessments within countries.
- Within-countries comparison of the PROBE score in PWH against national normative data [ Time Frame: 2 years ]Mean difference and standard deviation of the PROBE score in PWH against national normative data within countries.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03549858
|Contact: Mark Skinnerfirstname.lastname@example.org|
|Contact: Alfonso Iorioemail@example.com|
|Hamilton, Ontario, Canada, L8S4B2|
|Contact: Alfonso Iorio, MD 9055259140 ext 22421 firstname.lastname@example.org|